- Details
- The Decipher® Genomic Classifier has been shown to independently prognosticate outcomes in prostate cancer. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Alan Dal Pra presented an analysis validating the Decipher genomic classifier within the SAKK 09/10 trial. Dr. Alicia Morgans welcomes Dr. Dal Pra to discuss the SAKK 09/10 trial and to share his insights into this...
|
- Details
- The HERO study was a randomized, open-label, parallel-group study evaluating relugolix in men with advanced prostate cancer. Overall, 934 men with advanced prostate cancer underwent 2:1 randomization to receive relugolix 120 mg orally once daily after a single loading dose of 360 mg or leuprolide 3-month injections for 48 weeks. Subgroups analyzed by age were <65 years or ≥65 years and ≤75 years o...
|
- Details
- HPN424 is a prostate-specific membrane antigen (PSMA)-targeting T cell engager designed to redirect T cells to kill PSMA-expressing prostate cancer cells. It is engineered with three binding domains: anti-PSMA for tumor cell engagement, anti-albumin for half-life extension, and anti-CD3 for T cell engagement. Furthermore, HPN424 is optimized for small size and increased stability compared to other...
|
- Details
- In an oral presentation at the 2021 ASCO annual meeting, Andrea Necchi, MD provided a discussion on combination immunotherapy, checkpoint inhibitors, with radiation or chemoradiation approaches to bladder-sparing. In this conversation with Alicia Morgans, MD, MPH, he highlights several abstracts including a US phase II study presented by Arjun Balar of immunotherapy with pembrolizumab combined wit...
|
- Details
- Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able to...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...
|
- Details
- Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...
|
- Details
- In an educational session at the 2021 ASCO annual meeting titled Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer, Mark Fleming, MD presented on treatment sequencing in castrate-resistant metastatic cancer (CRPC). In this conversation with Charles Ryan, MD, he speaks to the complex therapeutic landscape and offers guidance in managing treatment se...
|
- Details
- This conversation with Alicia Morgans, MD, MPH, Petros Grivas, MD, PhD, highlights a post hoc analysis of the JAVELIN Bladder 100 trial which further characterizes the efficacy of avelumab first-line maintenance of time to end of next-line therapy. In JAVELIN Bladder 100, eligible patients had unresectable locally advanced or metastatic urothelial carcinoma without disease progression with 4 to 6...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Tian Zhang, MD, highlights a phase II trial lead by Sumanta Kumar (Monty) Pal evaluating the efficacy and safety of cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has metastasized, presented at ASCO 2021. Berzosertib is an ATR inhibitor with preclinical data suggestive of...
|
